{"title":"乳腺 X 线照相术乳腺密度测定与乳腺癌激素受体状态的关系。","authors":"Shweta Priti, Rashmi Dixit, Anju Garg, Nita Khurana, Rajdeep Singh","doi":"10.5114/pjr/187679","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the most frequent cancer in women, with significant mortality. Mammography is a routine investigation for breast disease. A known risk factor for breast cancer is increased breast density. Here, we tried to observe if mammographic density also affects the hormone receptor status of breast cancer, which will help in the understanding of the biological mechanisms of breast cancer development.</p><p><strong>Material and methods: </strong>Suspected breast cancer patients at Lok Nayak Hospital, Delhi, underwent mammography in the Department of Radiodiagnosis. The density of breast contralateral to the mass was assessed using Hologic Quantra software version 2.1.1 [Area Breast Density(ABD)]. The hormone receptor status of all the tumours was recorded on histopathology. Of these, 100 confirmed cases were included in the study.</p><p><strong>Results: </strong>ER-positive, PR-positive, and HER2-positive tumours were seen in 41%, 33%, and 34% patients, respectively. Regarding ER receptor status, the mean ABD for positive and negative tumours was 27% and 23%, respectively, <i>p</i>-value = 0.01, showing significant relation between them. Mean ABD for HER2-positive and -negative tumours was 25% and 24%, respectively, <i>p</i>-value = 0.75. Mean ABD for PR-positive and PR-negative tumours was 23% and 25%, respectively, <i>p</i>-value = 0.42 (not significant).</p><p><strong>Conclusions: </strong>We found that ER-positive tumours were common in dense breasts, which was statistically significant. However, this was not true for PR and HER2 receptor status. Limited studies have been done to study MD using computerised software and its effect on hormone receptor status, with conflicting results. Further, large, multicentric studies can be useful in understanding the mechanism and providing better treatment for breast cancer patients.</p>","PeriodicalId":94174,"journal":{"name":"Polish journal of radiology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262017/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of mammographic breast density measurements and hormone receptor status of breast cancer.\",\"authors\":\"Shweta Priti, Rashmi Dixit, Anju Garg, Nita Khurana, Rajdeep Singh\",\"doi\":\"10.5114/pjr/187679\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Breast cancer is the most frequent cancer in women, with significant mortality. Mammography is a routine investigation for breast disease. A known risk factor for breast cancer is increased breast density. Here, we tried to observe if mammographic density also affects the hormone receptor status of breast cancer, which will help in the understanding of the biological mechanisms of breast cancer development.</p><p><strong>Material and methods: </strong>Suspected breast cancer patients at Lok Nayak Hospital, Delhi, underwent mammography in the Department of Radiodiagnosis. The density of breast contralateral to the mass was assessed using Hologic Quantra software version 2.1.1 [Area Breast Density(ABD)]. The hormone receptor status of all the tumours was recorded on histopathology. Of these, 100 confirmed cases were included in the study.</p><p><strong>Results: </strong>ER-positive, PR-positive, and HER2-positive tumours were seen in 41%, 33%, and 34% patients, respectively. Regarding ER receptor status, the mean ABD for positive and negative tumours was 27% and 23%, respectively, <i>p</i>-value = 0.01, showing significant relation between them. Mean ABD for HER2-positive and -negative tumours was 25% and 24%, respectively, <i>p</i>-value = 0.75. Mean ABD for PR-positive and PR-negative tumours was 23% and 25%, respectively, <i>p</i>-value = 0.42 (not significant).</p><p><strong>Conclusions: </strong>We found that ER-positive tumours were common in dense breasts, which was statistically significant. However, this was not true for PR and HER2 receptor status. Limited studies have been done to study MD using computerised software and its effect on hormone receptor status, with conflicting results. Further, large, multicentric studies can be useful in understanding the mechanism and providing better treatment for breast cancer patients.</p>\",\"PeriodicalId\":94174,\"journal\":{\"name\":\"Polish journal of radiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262017/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Polish journal of radiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pjr/187679\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polish journal of radiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pjr/187679","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:乳腺癌是女性最常见的癌症,死亡率很高。乳房 X 射线照相术是乳腺疾病的常规检查。乳腺密度增加是乳腺癌的一个已知风险因素。在此,我们试图观察乳腺密度是否也会影响乳腺癌的激素受体状态,这将有助于了解乳腺癌发展的生物学机制:德里 Lok Nayak 医院的疑似乳腺癌患者在放射诊断部接受了乳房 X 线照相术。使用 Hologic Quantra 软件 2.1.1 版评估肿块对侧乳房的密度[面积乳房密度(ABD)]。组织病理学检查记录了所有肿瘤的激素受体状态。其中,100 例确诊病例被纳入研究:结果:ER 阳性、PR 阳性和 HER2 阳性的肿瘤患者分别占 41%、33% 和 34%。在ER受体状态方面,阳性和阴性肿瘤的平均ABD分别为27%和23%,P值=0.01,显示两者之间存在显著关系。HER2阳性和阴性肿瘤的平均ABD分别为25%和24%,p值=0.75。PR阳性和PR阴性肿瘤的平均ABD分别为23%和25%,P值=0.42(不显著):我们发现ER阳性肿瘤常见于致密乳房,这在统计学上有显著意义。结论:我们发现ER阳性肿瘤常见于致密型乳房,这在统计学上有意义,但PR和HER2受体状态并非如此。使用计算机软件对MD及其对激素受体状态的影响进行的研究有限,结果相互矛盾。此外,大型多中心研究有助于了解其机制,并为乳腺癌患者提供更好的治疗。
Association of mammographic breast density measurements and hormone receptor status of breast cancer.
Purpose: Breast cancer is the most frequent cancer in women, with significant mortality. Mammography is a routine investigation for breast disease. A known risk factor for breast cancer is increased breast density. Here, we tried to observe if mammographic density also affects the hormone receptor status of breast cancer, which will help in the understanding of the biological mechanisms of breast cancer development.
Material and methods: Suspected breast cancer patients at Lok Nayak Hospital, Delhi, underwent mammography in the Department of Radiodiagnosis. The density of breast contralateral to the mass was assessed using Hologic Quantra software version 2.1.1 [Area Breast Density(ABD)]. The hormone receptor status of all the tumours was recorded on histopathology. Of these, 100 confirmed cases were included in the study.
Results: ER-positive, PR-positive, and HER2-positive tumours were seen in 41%, 33%, and 34% patients, respectively. Regarding ER receptor status, the mean ABD for positive and negative tumours was 27% and 23%, respectively, p-value = 0.01, showing significant relation between them. Mean ABD for HER2-positive and -negative tumours was 25% and 24%, respectively, p-value = 0.75. Mean ABD for PR-positive and PR-negative tumours was 23% and 25%, respectively, p-value = 0.42 (not significant).
Conclusions: We found that ER-positive tumours were common in dense breasts, which was statistically significant. However, this was not true for PR and HER2 receptor status. Limited studies have been done to study MD using computerised software and its effect on hormone receptor status, with conflicting results. Further, large, multicentric studies can be useful in understanding the mechanism and providing better treatment for breast cancer patients.